Prof. William (Liam) M. Gallagher
Prof. William (Liam) M. Gallagher is co-founder and Chief Scientific Officer of OncoMark. He is currently the Director of the University College Dublin (UCD) Conway Institute of Biomolecular and Biomedical Research, where he also holds an academic post as Professor of Cancer Biology. From September 2009 - August 2011 Liam was the Vice-Principal for Research and Innovation within the UCD College of Life Sciences.
Nationally, Liam is currently the Director of BREAST-PREDICT, which is the first Irish Cancer Society Collaborative Cancer Research Centre (CCRC) to be funded. This country-wide CCRC, which is supported to the level of 7.5 million euro, runs from 2013 to 2018 and involves 6 academic institutions (UCD, TCD, RCSI, DCU, NUIG and UCC), as well as the not-for-profit clinical trials organisation, the All-Ireland Co-Operative Oncology Research Group (ICORG).
Liam was also a co-PI and Deputy Co-ordinator of a major Science Foundation Ireland-funded Strategic Research Cluster, Molecular Therapeutics of Cancer (2009-2014). He has co-ordinated two Marie Curie Industry Academia Partnerships and Pathways (IAPPs) projects under FP7, namely FAST-PATH (www.fastpathproject.com) and SYS-MEL (www.sysmel.com). He is also Co-ordinator of a large-scale, multi-million euro, FP7 collaborative project, entitled RATHER (www.ratherproject.com). Liam’s research group has also been involved in several other FP7 research programmes as partners, including MEL-PLEX (www.melplex.eu), AngioTox (www.angiotox.com) and AngioPredict. (www.angiopredict.com). He also co-ordinated an analogous FP7 IAPP Programme, Target-Melanoma (www.targetmelanoma.com).
Liam has received a number of awards for his research and innovation achievements in the oncology arena, including the BACR/AstraZeneca Young Scientist Frank Rose Award in 2004, the St. Luke’s Silver Medal Award in 2008, the NovaUCD 2011 Innovation Award and the inaugural Irish Association for Cancer Research Medal in 2017. He has filed/been awarded multiple patents and has acted as consultant for a wide variety of industrial parties within the biomedical sphere.